peginterferon beta-1a (Plegridy)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical Editor: Charles Patrick Davis, MD, PhD
    Charles Patrick Davis, MD, PhD

    Charles Patrick Davis, MD, PhD

    Dr. Charles "Pat" Davis, MD, PhD, is a board certified Emergency Medicine doctor who currently practices as a consultant and staff member for hospitals. He has a PhD in Microbiology (UT at Austin), and the MD (Univ. Texas Medical Branch, Galveston). He is a Clinical Professor (retired) in the Division of Emergency Medicine, UT Health Science Center at San Antonio, and has been the Chief of Emergency Medicine at UT Medical Branch and at UTHSCSA with over 250 publications.

GENERIC NAME: peginterferon beta-1a

BRAND NAME: Plegridy

DRUG CLASS AND MECHANISM: Peginterferon beta-1a (Plegridy) is a protein produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary Cells into which the human interferon beta genes have been introduced. It is used for treating multiple sclerosis (MS). It differs from interferon beta-1a by having polyethylene glycol attached to the interferon molecules (peglated) that allow the interferon to remain in the body for longer times thus allowing less frequent dosing. Interferon beta-1a is designed to be identical to interferon beta that is naturally produced by various cells in the body. Interferon beta has antiviral properties and plays a role in regulating the immune response. The exact mechanism by which interferon beta-1a works in the body to treat MS is not known. Interferon beta-1a does not cure MS. Rather it helps to decrease the number of flare-ups and slows the occurrence of some of the physical disability that commonly occurs in the disease. Plegridy works in the same way and has similar side effects as other interferon beta-1a products such as Avonex and Rebif. However, it is given every 14 days versus once weekly or 3 times per week injections. The FDA approved Plegridy in August, 2014.

PRESCRIBED FOR: Interferon beta-1a is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS) in adults.

The safety and effectiveness of peginterferon beta-1a has not been established in people under 18 or over 65 years of age.

SIDE EFFECTS: The most common side effects of interferon beta-1a are:

Quick GuideMultiple Sclerosis (MS) Symptoms and Treatment

Multiple Sclerosis (MS) Symptoms and Treatment
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Newsletters

Get the latest health and medical information delivered direct to your inbox!

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors